Table 1.
Peptides covering CCR5 extracellular regions and Ig reactivity obtained with LTNP samples
|
CCR5 external domain sequence
|
Ig reactivity
|
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Peptide | 4 | 11 | 20 | 21 | 22 | 152 | 110 | 173 | NY4 | NY6 | NY9 | NY10 | |
| 1 | MDYQVSSPIYDINYYTSEPC | — | — | — | — | — | — | — | — | ND | ND | ND | ND |
| 3 | cYAAAQWDFGNTMCQ | 5.2 | 5.4 | 4 | 7.4 | 5.9 | 6.8 | 8 | 7.7 | + | + | + | + |
| 4 | CSSHFPYSQYQFWKNFQTLKc | — | — | — | — | — | — | — | — | ND | ND | ND | ND |
A specific concentration of human Igs from the 12 LTNPs was obtained only when peptide 3 was used. CCR5 specific antibodies from some LTNP were quantified and expressed as percentage of total serum Igs. Ig reactivity was negative in all samples for peptide 2 with a CCR5 external domain sequence of YYTSEPCQKINVKQIAARLLP and for peptide 5 with a CCR5 external domain sequence of FQEFFGLNNCSSSNR. An unrelated peptide, with sequence of VQGEESNDK, was used as negative control.
ND indicates not done; —, Ig reactivity was negative; and +, that Ig reactivity was positive but not quantified.